# Fresenius Group account plan

> Fresenius is a German healthcare group: Fresenius Kabi (IV drugs, nutrition, MedTech, biosimilars) and Helios hospitals. €22,554 million 2025 revenue.

## At a glance

Fresenius SE & Co. KGaA, headquartered in Bad Homburg, Germany, is a therapy-focused healthcare group with two Operating Companies: Fresenius Kabi (generic IV drugs and fluids, clinical nutrition, MedTech and biosimilars) and Fresenius Helios (private hospitals in Germany and in Spain through Quirónsalud). It also holds a ~29% equity-accounted stake in Fresenius Medical Care. In 2025 revenue was €22,554 million (7% organic growth), EBIT before special items €2,595 million (11.5% margin) and Core EPS €2.87, with 178,394 employees; Europe is 74% of revenue and North America 12%. The Else Kröner-Fresenius-Stiftung held 27.1% of the shares at December 31, 2025.

## Business units

- **Fresenius Kabi - Pharma (IV Drugs & Fluids)** (€3,735 million 2025 revenue): Generic IV drugs in oncology, anaesthetics, anti-infectives and critical care, plus IV fluids, with a leading position in the U.S. and Europe. 2025 EBIT was €813 million at a 21.8% margin; U.S. pricing pressure and manufacturing adjustments cut Q2 2026 EBIT by 14%.
- **Fresenius Kabi - Nutrition** (€2,396 million 2025 revenue): Parenteral and enteral clinical nutrition, including the Fresubin range and multi-chamber bags; 5% organic growth in 2025, held back by the volume-based procurement tender for Ketosteril in China.
- **Fresenius Kabi - MedTech** (€1,610 million 2025 revenue): Infusion and nutrition pumps and disposables, including the Ivenix smart infusion system for the U.S., transfusion medicine, cell therapy devices and plasma collection. Revenue grew 11% in Q2 2026 on Ivenix installations at customers such as Mayo Clinic and SSM Health.
- **Fresenius Kabi - Biopharma** (€871 million 2025 revenue): Biosimilars for oncology and autoimmune diseases, vertically integrated with mAbxience; revenue rose 43% in 2025 on the Tyenne (tocilizumab) ramp-up and denosumab launches. The ambition is to double revenue and molecules by 2030 at an EBIT margin of around 20%.
- **Helios Germany** (€8,121 million 2025 revenue): More than 80 hospitals, more than 200 medical care centres and occupational health centres; the leading German acute-hospital operator with around 7% market share by admissions. EBIT was €662 million at an 8.2% margin in 2025; Dr. Christian Pawlu now leads Helios.
- **Helios Spain (Quirónsalud)** (€5,429 million 2025 revenue): 50 hospitals, around 100 outpatient centres and more than 300 occupational health facilities in Spain plus 7 hospitals in Latin America; leader of the Spanish private hospital market with a ~13% share. EBIT was €669 million at a 12.3% margin, and it uses AI tools such as Scribe for clinical documentation.

## Strategic priorities

- **#FutureFresenius Rejuvenate phase**: After Reset and Revitalize, the group is upgrading its core and scaling three platforms, (Bio)Pharma, MedTech and Care Provision, mainly organically with partnering, in-licensing and potentially bolt-on acquisitions.
- **Scale Kabi's growth vectors**: Kabi's structural EBIT margin band rises to 17-19% from 2026; products launched since 2023 generated more than €500 million of 2025 revenue, and Biopharma aims to double revenue by 2030.
- **Close the Helios performance gap**: Management calls Helios a clear priority for 2026: cluster strategy, administrative consolidation and case-mix management in Germany, within a 10-12% margin ambition.
- **Core EPS growth**: From 2026 Core EPS replaces EBIT as the guided metric; FY2026 Core EPS growth guidance was raised in August to 10-15% in constant currency.
- **Digital healthcare and AI**: A strategic partnership with SAP to build a digital healthcare ecosystem, AI tools at Quirónsalud and IT harmonisation and administrative digitalisation in Germany.

## Latest results

In Q2 2026 revenue was €5,864 million (6% organic) and EBIT before special items €719 million at a 12.3% margin, with Core EPS of €0.83 (+14%). Over H1 2026 revenue was €11,608 million (5% organic), EBIT €1,397 million and net income before special items €1,118 million (+14%). Kabi's growth vectors reached a 17.9% Q2 margin and Biopharma grew 37%, while Helios lifted its Q2 margin to 10.6%. Net debt fell to €10,138 million (2.6x). FY2026 guidance is 4-7% organic revenue growth and Core EPS growth of 10-15% in constant currency, raised from 5-10%.

## Investments and deals

- **Capex step-up**: Capex is guided at about 5.5% of revenue in 2026 (54% at Helios, 39% at Kabi), up from 4.4% in 2025, when property, plant and equipment spending was €1,001 million.
- **Kabi capacity**: Projects include high-speed infusion-bottle lines in Italy and Poland, a €36 million sip-feed line in the Netherlands, a multi-chamber bag line in China, €50 million in MedTech capacity and automation, and the Wilson, North Carolina plant ramp-up.
- **Biosimilar pipeline**: Acquisition spending of €392 million in 2025 went mainly to milestone payments for the biosimilars business acquired from Merck KGaA; vedolizumab filings were accepted in the U.S. and EU and rituximab won FDA approval.
- **Portfolio exits**: The Vamed exit is largely completed, about €1.1 billion was raised from FMC shares and an exchangeable bond in March 2025, and three German hospitals are being sold.

## Challenges and risks

- **German hospital financing**: The GKV contribution-rate stabilisation act limits DRG base-rate increases from January 1, 2027, and the hospital structure reform makes 60% of remuneration volume-independent.
- **U.S. tariffs and FDA oversight**: U.S. tariffs, the weaker dollar and other factors created several hundred million euros of headwinds in 2025; the Melrose Park, Illinois site received an FDA Official Action Indicated classification.
- **China volume-based procurement**: The Ketosteril tender in China weighed on Nutrition, and management says volume-based tendering is there to stay.
- **U.S. generics pricing and buyer concentration**: Pharma faces U.S. pricing pressure, and Kabi's U.S. sales depend on a limited number of buyers.
- **Middle East conflict and supply chain**: The conflict raised energy, transport and material cost risks in 2026.

## What leadership says

> "Helios is not yet delivering in line with our expectations. Closing this gap is a clear management priority for 2026 and beyond." — Michael Sen, Chief Executive Officer, Q4 and full-year 2025 results call, 25 February 2026

> "Q2 is another clear proof point that #FutureFresenius is delivering. We are converting operational momentum into earnings growth, higher returns, and stronger financial and strategic flexibility." — Michael Sen, Chief Executive Officer, Q2 2026 results call, 5 August 2026

> "R&D is not the leakage. R&D is securing your future." — Michael Sen, Chief Executive Officer, Q4 and full-year 2025 results call, 25 February 2026

> "We have more opportunities than we probably have funding for" — Sara Hennicken, Chief Financial Officer, Q4 and full-year 2025 results call, 25 February 2026


## Where a supplier can help

- **Hospital efficiency and automation at Helios**: Closing the Helios gap and answering the GKV stabilisation act with efficiency, automation and digitalisation programmes creates demand for administrative automation, case-mix analytics and IT harmonisation services.
- **Manufacturing quality and automation at Kabi**: The FDA classification at Melrose Park, which management sees as a chance to embed automation and digitisation, plus new production lines, favour GMP, quality and automation suppliers.
- **Clinical AI and digital platforms**: Quirónsalud's AI tools and the SAP digital healthcare ecosystem open room for clinical documentation, AI and data platform partners.
- **Supply chain resilience**: U.S. tariffs, the Middle East conflict and the Local-for-Local push create needs for alternative API sourcing, U.S. manufacturing and logistics partners.
- **Biosimilar commercialisation**: Doubling Biopharma by 2030 with new launches and direct health-plan contracting fits market access, distribution and CDMO capacity offers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Fresenius Annual Report 2025](https://www.fresenius.com/sites/default/files/2026-03/fresenius_annual_report_2025_0.pdf)

Annual report · 2026-03-25

- Fresenius SE & Co. KGaA (Bad Homburg, Germany) is a therapy-focused healthcare group with two Operating Companies: **Fresenius Kabi** (biopharmaceuticals, clinical nutrition, MedTech, generic IV drugs and IV fluids; 38% of 2025 revenue) and **Fresenius Helios** (Europe's leading private hospital operator, Helios Germany and Helios Spain/Quirónsalud; 60%). It also holds a ~29% equity-accounted stake in Fresenius Medical Care and the remaining Vamed activities (renamed VIACAMA).
- FY2025: revenue €22,554 million (7% organic growth), EBIT before special items €2,595 million (+6% in constant currency, 11.5% margin), net income before special items €1,995 million, Core EPS €2.87 (+12% in constant currency); 178,394 employees; Europe is 74% of revenue and North America 12%.
- Kabi: revenue €8,612 million, EBIT €1,413 million, 16.4% margin; the growth vectors (MedTech, Nutrition, Biopharma) earned €743 million EBIT (+17%), Biopharma revenue rose 43% to €871 million on the Tyenne biosimilar ramp-up. Structural EBIT margin band raised to 17-19% from 2026.
- Helios: revenue €13,550 million, EBIT €1,328 million, 9.8% margin; Helios Germany €8,121 million revenue at an 8.2% margin (energy relief funds fell away), Helios Spain €5,429 million at 12.3%.
- Strategy: #FutureFresenius has moved from Reset and Revitalize to the Rejuvenate phase (upgrade core, scale platforms, elevate performance) along three platforms: (Bio)Pharma, MedTech and Care Provision. Products launched since 2023 generated more than €500 million of 2025 revenue at an EBIT margin of around 20%; Biopharma aims to double revenue and molecules by 2030 at a ~20% EBIT margin.
- Balance sheet: net debt down to €10,348 million, leverage 2.7x net debt/EBITDA (corridor 2.5-3.0x), ROIC 6.6%; interest expense cut by more than €100 million; €1.1 billion raised from FMC shares and an exchangeable bond; dividend proposal €1.05 (+5%, ~37% payout).
- 2026 guidance: 4-7% organic revenue growth and 5-10% Core EPS growth in constant currency (Core EPS replaces EBIT as the guided metric); Kabi mid-to-high-single-digit growth at a 16.5-17% margin, Helios mid-single-digit growth at 10-10.5%; capex about 5.5% of revenue, 54% at Helios and 39% at Kabi.
- Leadership: CEO Michael Sen's mandate extended to 2031; Dr. Christian Pawlu joins the Management Board on July 1, 2026 to oversee Helios, succeeding Robert Möller.
- Top risks: acquisitions/investments/transformations (VIACAMA exit guarantees, IT harmonisation), economy and market conditions (U.S. tariffs, FDA delays, geopolitics), healthcare financing (German hospital reform, China volume-based procurement), and concentration of Kabi's U.S. sales on a limited number of buyers.

### [Fresenius Half-Year Financial Report H1 2026 (1st half and 2nd quarter 2026)](https://www.fresenius.com/sites/default/files/2026-08/half-year_financial_report_h1_2026_en.pdf)

Interim report · 2026-08-05

- Q2 2026: revenue €5,864 million (+5%, 6% organic), EBIT before special items €719 million (+10% in constant currency) at a 12.3% margin (+60 bps), Core EPS €0.83 (+14%).
- H1 2026: revenue €11,608 million (5% organic), EBIT €1,397 million (12.0% margin), net income before special items €1,118 million (+14%), Core EPS €1.65 (+14% in constant currency); reported net income €817 million.
- Guidance raised: FY2026 Core EPS growth now 10-15% in constant currency (previously 5-10%); Kabi's EBIT margin expected at the upper end of 16.5-17%; organic revenue growth guidance unchanged at 4-7%.
- Fresenius Kabi Q2: revenue €2,244 million (7% organic), EBIT €382 million, 17.0% margin; growth vectors €1,309 million (+12%) at a 17.9% margin, within the 17-19% band for the first time; Biopharma +37% to €260 million on Tyenne and denosumab; MedTech +11% on Ivenix pump installations; Pharma EBIT down 14% on manufacturing adjustments.
- Fresenius Helios Q2: revenue €3,526 million (5% organic), EBIT €374 million (+11%), margin 10.6%; Helios Germany margin 8.3% helped by the surcharge on invoices of publicly insured patients; Helios Spain margin 14.0%.
- Balance sheet: net debt €10,138 million, leverage 2.6x, ROIC 6.9%, LTM cash conversion 1.2; S&P outlook revised to positive (BBB); €1.05 dividend paid (€591 million).
- New risks: Germany's GKV contribution-rate stabilisation act (from 2027, caps on DRG base-rate increases), the Middle East conflict (energy, transport, materials) and an FDA "Official Action Indicated" classification at Kabi's Melrose Park, Illinois site.

### [Fresenius Q4 and full-year 2025 results conference call (transcript)](https://www.fresenius.com/sites/default/files/2026-02/fresenius_transcript_q425_20260225.pdf)

Executive talk · Michael Sen, Chief Executive Officer (with Sara Hennicken, Chief Financial Officer) · 2026-02-25

- CEO Michael Sen called 2025 "a great year" and said "2026 will be all about accelerating performance and ultimately creating sustainable value"; Q4 2025 organic growth was 9%, EBIT +13% in constant currency, Core EPS +16%.
- Kabi's structural EBIT margin band is raised to 17-19%; more than €0.5 billion of 2025 revenue came from new products; Pharma is expected to hold a margin of around 20%.
- Biopharma: Q4 growth of 97%; Tyenne holds 37% market share in EU4 + UK and 17% in the U.S.; more than 100 denosumab contracts signed in the U.S.; plan to double revenue by 2030 at a ~20% EBIT margin.
- Sen was blunt on Helios: "Helios is not yet delivering in line with our expectations. Closing this gap is a clear management priority for 2026 and beyond."
- Guidance switches from EBIT to Core EPS: 4-7% organic growth and 5-10% Core EPS growth; Kabi 16.5-17% margin, Helios 10-10.5%; group EBIT margin around 11.5%; capex around 5.5% of revenue (2025: 4.4%).
- Tariffs: 90% of group revenues are unaffected by U.S. tariffs and 70% of the U.S. medicine is produced domestically; the Supreme Court ruling is not reflected in guidance.
- CFO Sara Hennicken: net debt down around €3 billion in two years; net interest cut by more than €100 million; dividend €1.05 (+5%); Helios Germany's DRG inflator falls from about 5.9% to 2.98% but a 3.25% surcharge offsets it in 2026.

### [Fresenius Q2 2026 results conference call (transcript)](https://www.fresenius.com/sites/default/files/2026-08/fresenius_transcript_q226_20260805.pdf)

Executive talk · Michael Sen, Chief Executive Officer (with Sara Hennicken, Chief Financial Officer) · 2026-08-05

- Michael Sen: Q2 2026 is "another clear proof point that #FutureFresenius is delivering"; Core EPS +14% at constant currency, EBIT +10%, group EBIT margin 12.3%; FY2026 Core EPS growth guidance raised to 10-15%.
- Kabi's growth vectors grew 12% organically with a margin of 17.9%; Biopharma grew 38% organically; Tyenne holds 44% market share in the top 5 EU countries and 30% in the U.S.; Bomyntra 11% across the EU5.
- Pipeline: vedolizumab biosimilar filings accepted in the U.S. and EU (decision expected next year), FDA approval of rituximab, 7 new Pharma in-licensing agreements in H1.
- FDA: Melrose Park received "Official Action Indicated" status; Sen does not expect a material impact on production, supply or 2026 results.
- Helios: Germany's GKV Stabilization Act is "more favorable than the earlier draft proposals"; Fresenius expects Helios EBIT growth in 2027 and keeps the 10-12% margin ambition.
- Capital: leverage 2.6x, ROIC 6.9%, a €1 billion bond in July; the FMC stake is "just an investment" and Fresenius may deploy capital to scale its platforms, including a new Fresenius Venture initiative.
- China: volume-based tendering "is there to stay"; China Nutrition seen flat in H2, with growth "if at all, in 2027".

### [Michael Sen at the J.P. Morgan 2026 Healthcare Conference (presentation and Q&A transcript)](https://www.fresenius.com/sites/default/files/2026-01/jpm-2026-transcrip-fresenius-se-co-kgaa.pdf)

Executive talk · Michael Sen, Chief Executive Officer · 2026-01-14

- At the J.P. Morgan Healthcare Conference (January 14, 2026), Michael Sen presented Fresenius as a full-spectrum "healthcare company" in "a new world order" where healthcare "is a key element for resilience, for wealth, and also for security".
- Kabi, "the industrial side", is "three plus one": Pharma (number one in IV drugs, number three in fluids, ~22% EBIT margin), Nutrition (roughly a two-and-a-half-billion business), MedTech and Biopharma; Helios is the largest hospital chain in Germany and in Spain (Quirónsalud).
- Biopharma: "a little shy of a billion" in 2025 sales, expected to reach one billion in 2026 and to double by 2030 with ~20% profitability potential.
- The big portfolio moves are done; Rejuvenate "means we can play offense", with capital going to R&D, growth capex, in-licensing and possibly bolt-on M&A; asked about splitting Kabi and Helios, he said no business is holding back the others.
- U.S.: Fresenius covers roughly 70% of the FDA essential medicine list and manufactures roughly 70% of what it sells in the U.S.; the Wilson, North Carolina plant is ramping up.
- China: "VBP is there to stay"; Germany 2026: the hospital surcharge and €2 billion of cuts are "a wash"; FMC: "We are a shareholder, nothing more."

## Questions about Fresenius Group

### What does Fresenius do?

Fresenius runs Fresenius Kabi, which makes generic IV drugs and fluids, clinical nutrition, infusion devices and biosimilars, and Fresenius Helios, which operates private hospitals in Germany and Spain.

### What was Fresenius' revenue in 2025?

Revenue was €22,554 million in 2025 with 7% organic growth, EBIT before special items of €2,595 million and Core EPS of €2.87.

### How many employees does Fresenius have?

178,394 employees at the end of 2025, and 178,486 at June 30, 2026; Helios accounts for 130,240 of the 2025 total.

### Who leads Fresenius?

Michael Sen is CEO, with his mandate extended to 2031; Sara Hennicken is CFO, Pierluigi Antonelli oversees Fresenius Kabi and Dr. Christian Pawlu oversees Helios from July 1, 2026.

### What is Fresenius' strategy?

Under #FutureFresenius it is scaling three platforms, (Bio)Pharma, MedTech and Care Provision, growing biosimilars and MedTech while lifting Helios margins and Core EPS.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
